HIGH-THROUGHPUT NOVEL ANTIMICROBIAL DISCOVERY FROM 'OMIC DATASOURCES
Find novel antimicrobials in any digital biological data
AMPLY is a bioinformatics pipeline designed to take any form of digital biological data and retrieve novel antimicrobial peptides (AMPs) for synthesis and screening against multi-drug resistant (MDR) strains of bacteria and fungi.
THE DISCOVERY CYCLE
Bulk peptide synthesis via commercial systhesis partners. Different quality and pricing thresholds allow for focused or wide coverage, from tens to potentially thousands of putative compounds
What are AMPs?
Antimicrobial peptides (AMPs) are evolutionarily ancient weapons; part of the innate immune response found among all classes of life and are potent, broad spectrum antibiotics which demonstrate potential as novel therapeutic agents. AMPs have been demonstrated to kill Gram negative and Gram positive bacteria, enveloped viruses, fungi and even transformed or killed cancerous cells. Locating novel AMPs may prove to be a critical therapeutic avenue of the future to aid in the fight against antibiotic resistant bacteria.
AMP detection using tradition pattern-based matching in 'omic datasets can return limited results. Detection often relies on a “balance of proof” and complex comparisons across a variety of analysis techniques. AMPLY is a tool designed to identify AMPs by separating them from 'omic “background noise”. At the heart of AMPLY are multiple detection engines which characterise prospective peptides with potentially desirable properties. A comparative presentation dashboard allows the end user to rapidly assess these identified prospects and determine their suitability for synthesis and lab testing.
The AMPLY Team
AMPLY is a service provided by Ben Thomas a postdoctoral researcher supported by Aberystwyth University (Wales, UK), Queen's University (Belfast, UK) and is part of Prof. Chris Creevey's Creevey Lab (creeveylab.org). Funding for the tool comes from Life Science Research Network Wales, Aberystwyth University and Queen's University. Key peptide synthesis partners are St. George's University Hospital London (Tika Diagnostics) and Genscript, HK.
The photo on this page is provided by Jurnorain Gani (via the St. George's Univeristy, London maging facility) and shows E. coli bacteria being killed after 10 minutes exposure to a novel AMP identified by the AMPLY pipeline. All images and text on these pages is copyright and should not be reproduced without permission.